IP Library Granted Patent US 8,685,107
Granted Patent B2
US 8,685,107 · App. 11/894,124 · Granted Apr 1, 2014

Double-structured tissue implant and a method for preparation and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,107
App. No.
11/894,124
Granted
Apr 1, 2014
Kind
B2
Abstract

A double-structured tissue implant and a method for preparation and use thereof for implantation into tissue defects. The double-structured tissue implant comprising a primary scaffold and a secondary scaffold consisting of a soluble collagen solution in combination with a non-ionic surfactant generated and positioned within the primary scaffold. A stand alone secondary scaffold implant or unit. A process for preparation of the double-structured implant or the stand alone secondary scaffold comprising lyophilization and dehydrothermal treatment.

Claims (11)

1. A double-structured collagen implant comprising

an acellular, three-dimensional scaffold comprising a plurality of pores; and

a composition comprising a collagenous solution or gel and a surfactant that fills the plurality of pores to form a fibrous and cross-linked collagen network within said plurality of pores; and

a pharmaceutical agent incorporated into the scaffold, composition, or both.

2. The double-structured collagen implant of claim 1 , wherein the pharmaceutical agent is selected from growth and morphogenic factors, cytokines, membrane associated factors that promote growth and morphogenesis, cell attachment or adhesion proteins, hormones, pericellular matrix molecules, nutrients, nucleic acids, anti-neoplastic agents, anti-neoplastic agents, anti-inflammatory agents, enzymes, and metabolic inhibitors.

3. The double-structured collagen implant of claim 2 , wherein the anti-neoplastic agent is methotrexate or aminopterin.

4. The double-structured collagen implant of claim 2 , wherein the metabolic inhibitor is an RNAi, a cyclohexamide, or a steroid.

5. The double-structured collagen implant of claim 1 , further comprising living cells.

6. The double-structured collagen implant of claim 1 , wherein the implant comprises a primary scaffold comprising a porous collagen-containing material and a secondary scaffold comprising a soluble collagen and a nonionic surfactant.

7. The double-structured collagen implant of claim 6 , wherein the soluble collagen is soluble in acidic or basic solutions.

8. The double-structured collagen implant of claim 6 , wherein the nonionic surfactant comprises a copolymer of polyoxyethylene and polyoxypropylene.

Assignments (3)
CHANGE OF NAME Recorded Jun 29, 2022
From: HISTOGENICS CORPORATION
To: OCUGEN, INC.
Reel/Frame 060541/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2007
From: CLAESSON, HANS PETER INGEMAR; TARRANT, LAURENCE J.B.; SMITH, ROBERT LANE; SHORTKROFF, SONYA
To: HISTOGENICS CORPORATION
Reel/Frame 019782/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2007
From: CLAESSON, HANS PETER INGEMAR; TARRANT, LAURENCE J.B.; SMITH, ROBERT LANE; SHORTKROFF, SONYA
To: HISTOGENICS CORPORATION
Reel/Frame 019882/0851 →